ITALIAN PRIMARY IMMUNODEFICIENCIES STRATEGIC SCIENTIFIC COMMITTEE

CHRONIC GRANULOMATOUS DISEASE

Recommendations for diagnosis and treatment

Final Version: January 2001
Update: April 2004

Cohordinator Primary Immunodeficiencies Network:

Prof. Alberto G. Ugazio
Ospedale Bambin Gesù
Roma

Scientific Committee:

Prof. L Armenio (Bari)
Prof. M. Bonamico (Roma)
Prof. D. De Mattia (Bari)
Prof. M. Duse (Brescia)
Prof. G.L. Marseglia (Pavia)
Dott. B. Martire (Bari)
Prof. M. Masi (Bologna)
Prof. L.D. Notarangelo (Brescia)
Prof. G. Paolucci (Bologna)
Prof. A. Pession (Bologna)
Prof. M.C. Pietrogrande (Milano)
Prof. C. Pignata (Napoli)
Prof. A. Plebani (Brescia)
Dott. I. Quinti (Roma)
Prof. P. Rossi (Roma)
Prof. A. Stabile (Roma)
Prof. PA. Tovo (Torino)
Prof. A. Vierucci (Firenze)

Responsible:

Prof. Domenico De Mattia
Dott. Baldassarre Martire
Dipartimento di Biomedicina dell'Età Evolutiva
Università degli Studi di Bari

Data Review Committee:

Prof. Domenico De Mattia (BA)
Dott. Baldassarre Martire (BA)
Prof. Alessandro Plebani (BS)
Dott.ssa Annarosa Soresina (BS)
Dott. Roberto Rondelli (BO)

Data management and analysis:

Centro Operativo AIEOP
Pad. 23
c/o Centro Interdipartimentale di Ricerche sul Cancro "G. Prodi"
Via Massarenti, 9
40138 Bologna

CENTRES

CODE AIEOP	INSTITUTION	RAPRESENTATIVE
0901	ANCONA Clinica Pediatrica Ospedale Salesi ANCONA Tel.071/36363 Fax 071/36281	Prof. Coppa Prof. P.Pierani
0311	ASOLA(MN) Divisione di Pediatria Ospedale di Asola Tel. 0376/721309 Fax 0376/720189	Dott.G.Gambaretto
1301	BARI Dipart. Biomed.dell'Età Evolutiva Clinica Pediatrica I P.zza G. Cesare 11 70124 BARI Tel. 080/5542295 Fax 080/5542290 e-mail: demattia@bioetaev.uniba.it baldo.martire@bioetaev.uniba.it	Prof. D. De Mattia Dott.B.Martire
1307	BARI Clinica Pediatrica III Università di Bari P.zza Giulio Cesare 11 70124 BARI Tel. 080/5592844 Fax 080/5478911 e-mail:fabiocardinale@libero.it	Prof. L. Armenio Dott. F. Cardinale
1306	BARI Dip.di Scienze Biomediche e Oncologia umana Sez. Medicina Interna Policlinico P.zza G. Cesare 11 70125 BARI Tel. 080/5478822-860 Fax 080/5478820	Prof. F. Dammacco Dott.ssa M. Prete
0603	BOLOGNA Clinica Pediatrica Via Massarenti 11 40138 BOLOGNA Tel. 051/6363649 Fax 051/6364679 e-mail: paolucci@almadns.unibo.it masi@med.unibo.it	Prof. G.Paolucci Prof. M. Masi Dott.ssa A. Miniaci
0605	BOLOGNA Div. Pediatria Ospedale "Maggiore" Largo Nigrisoli, 2 40133 BOLOGNA Tel. 051/6478564 Fax 051/6478949	Prof. G. Ambrosioni Dott.ssa P.Alvisi
0305	BRESCIA Clinica Pediatrica Spedali Civili P.le Spedali Civili, 1 25123 BRESCIA Tel. 030/3995887- 700 Fax 030/3388099 e-mail: plebani@med.unibs.it soresina@master.cci.unibs.it duse@master.cci.unibs.it notarang@med.unibs.it	Prof. L.D. Notarangelo Prof. A. Plebani Prof. M. Duse Dott.ssa A. Soresina

1602	CAGLIARI Centro TMO Ospedale Microcitemico Clinica Pediatrica Univ. Cagliari Via Jenner 09121 CAGLIARI Tel. 070/6095512 Fax 070/6095694 e-mail: fcossu@mcweb.unica.it	Prof. Cao Dott. F. Cossu
1603	CAGLIARI Allergologia e Immunol. Clinica Policlinico Universitario Via S.Giorgio 12 09124 CAGLIARI Tel.070/60286240 Fax 070/60286212 e-mail: manconip@pacs.unica.it	Prof. S. Del Giacco Prof. P. Manconi
1901	CAMPOBASSO Div. Pediatrica Ospedale Cardarelli ASL3 Centromolise Campobasso Località Tappino 86100 Campobasso Tel. 0874/4092272 Fax 0874/4092273	Dott. I. Evangelista
1401	CATANZARO Div. Ematologia Ospedale Civile “A. Pugliese” Viale Pio X 88100 CATANZARO Tel. 0961/883069/883205 Fax 0961/883250 e-mail saveriomagro@libero.it	Dott. S. Magro Dott. S. Morgione
1404	CATANZARO U.O. di Pediatria Univ. degli Studi di Catanzaro Ospedale Pugliese Viale Pio X 88100 CATANZARO Tel. 0961/ 883007 Fax 0961/883489/727305 e-mail pstrisciuglio@unicz.it elisa.anastasio@tin.it	Prof. P. Strisciuglio Dott.ssa E.Anastasio
1502	CATANIA Div. Ematologia-Oncologia Ped. Clin. Pediatrica Università Catania Via A. Doria, 6 95123 CATANIA Tel. 095/256497 Fax 095/330636/222532 e-mail: antoscio@hotmail.com	Prof. G. Schillirò Dott. ssa A. Sciotto
0312	COMO Divisione Pediatria Azienda Osped. “Sant’Anna” Via Napoleone 60 22100 COMO Tel. 031/5855353 Fax 031/5855948 e-mail: pediatria@hsacomo.org	Dott. Maurizio. Sticca
403	COSENZA U.O. Pediatria Ospedale "Annunziata" Via Migliori 1 87100 Cosenza tel.0984/681343 Fax 0984/681315 luicarp@libero.it	Dott.ssa M. Candusso Dott. L. Carpino
0701	FIRENZE	Prof. G. Bernini

	Dipart. di Pediatria Ospedale "A. Meyer" Via L. Giordano, 13 50132 FIRENZE Tel. 055/5662542 Fax 055/570380 e-mail: azzaric@unifi.it c.azzari@meyer.it	Dott.ssa C. Azzari
0202	GENOVA Seconda Divis. Pediatria Istituto G. Gaslini P.zza G. Gaslini 5 16147 GENOVA Tel. 010/5636428 FAX 010/3776590 e-mail: eliocastagnola@ospedale-gaslini.ge.it marcogattorno@ospedale-gaslini.ge.it	Dott. E. Castagnola Dott. M.Gattorno
0315	MANTOVA Pediatria Ospedale Poma Via Albertoni 1 46100 MANTOVA Tel. 0376/201454 Fax 0376/201772	Dott. G. Pastorelli Dott.ssa S. Fasoli Dr. Gambaretto
1504	MESSINA Genetica e Immunologia Pediatrica Az. "G.Martino" Via Consolare Valeria Gazzi 98100 MESSINA Tel. 090/2213114 e-mail: carmelo.salpietro@unime.it	Prof. C. Salpietro
0314	MILANO Clinica Pediatrica II Università di Milano Via Commenda 9 20122 MILANO Tel. 02/57992496 Fax 02/50320210 e-mail: mariacristina.pietrogrande@unimi.it	Prof.ssa MC. Pietrogrande Dott.ssa F. Rusconi Dott.ssa RM. DellePiane Dott.ssa Panisi
0316	MILANO Ist. Clinici Perfezionamento Div. Medicina Generale P.zza San Barnaba 8 20123 MILANO Tel. 02/57992672 FAX 02/57992659	Dott. G. Cambiaghi
0317	MILANO Dip. Medicina e Chirurgia Università di Milano Pol San Marco Corso Europa 7 24040 ZINGONIA-OSIO SOTTO Tel. 035/886308 FAX 035/886308 e-mail: maurizio.pietrogrande@unimi.it	Prof. M. Pietrogrande
0318	MILANO Un.di ricerca Clin Pediatrica HSR TIGET Istituto Scientifcico HS Raffaele Via Olgettina 58 MILANO Tel. 02/26434668 Fax 02/26434671 e-mail: m.roncarolo@hsr.it a.aiuti@hsr.it	Prof.ssa MG. Roncarolo Dott. A. Aiuti
0302	MONZA Clinica Pediatrica Ospedale "S. Gerardo" Via Donizetti 106	Prof. G. Masera Prof. A. Biondi Dott.ssa A. Sala

	20052 MONZA Tel. 039/2333513 Fax 039/2301646 e-mail: masera@xquasar.it	
1207	NAPOLI Unità Specialistica di Immunologia Dipart. di Pediatria Univ. Studi di Napoli "Federico II" Via Pansini 5 80131 NAPOLI Tel. 081/664632 Fax 081/5451278 e-mail: pignata@unina.it	Prof. C. Pignata
1203	NAPOLI Divisione di Pediatria-Ematologia Ospedale "Pausilipon" Via Posillipo 226 80123 NAPOLI Tel. 081/2205410 Fax 081/2205418	Prof. V. Poggi Dott. G. Menna
1208	NAPOLI I Div. Med. Pediatrica Ospedale Santobono Via M. Fiore 6 80100 NAPOLI Tel. 081/2205636 Fax 081/2205608	Dott. R. Di Nardo
1209	NAPOLI Pediatria Ospedale S. Leonardo ASL NA5 Via Castellammare di Stabia 80054 GRAGNANO (NA) Tel. 081/8711782 Fax 081/8729341 e-mail: adapuzzo@libero.it	Dott. A. D'Apuzzo
1210	NAPOLI I Div. Pediatria Osp. SS. Annunziata Via Egiziaca A Forcella 80139 NAPOLI Tel. 081/2542504– 2600 Fax 081/2542635 antpelliccia@tiscali.it	Dott. A. Pelliccia
1204	NAPOLI II Pediatria Ospedale Annunziata ASLNA1 Tel. 081/2542544-634 Fax 081/2542635	Dott. A. Correra
1211	NAPOLI Centroperladiagnosi e cura ID prim. Immunologia e Allergologia Clinica Univ. Studi di Napoli "Federico II" Via Pansini 5 80131 NAPOLI Tel. 081/7462261, FAX 081/2203998 e-mail: spadaro@unina.it	Prof. G. Marone Dott. G. Spadaro
0401	PADOVA Clinica Oncoematol. Pediatrica Università di Padova Via Giustiniani 3 35128 PADOVA Tel. 049/8218003 FAX 049/8213510 e-mail: luigi.zanesco@unipd.it giuseppe.basso@unipd.it mariacaterina.putti@unipd.it	Prof. L. Zanesco Prof. G. Basso Dott. MC. Putti

0410	PADOVA Dip. Medicina Clinica e Sperim. Immunologia Clinica Via Giustiniani 2 35128 PADOVA Tel. 049/8212299 FAX 049/8754179 e-mail: carlo.agostini@unipd.it	Prof. G. Semenzato Prof. C. Agostini
1505	PALERMO U.O. Clinica Pediatrica Via Benedettini 1 90100 PALERMO Tel. 091/6666038 - 6249 Fax 091/421630 e-mail: istped@mbox.unipa.it	Prof. GM. Amato
1501	PALERMO Oncoematologia Pediatrica Via Benedettini 1 90100 PALERMO Tel. 091/6666130-015 Fax 091/421630 e-mail:arico@ospedalecivicopa.org	Dott.M.Aricò Dott.A.Trizzino
0601	PARMA Oncoematologia Pediatrica Dip. di Pediatria Az. Ospedaliera di Parma Via A. Gramsci 14 43100 PARMA Tel. 0521/702222/702210 Fax 0521/702360 e-mail: gcizzi@ao.pr.it pbertolini@ao.pr.it	Dott. G. Izzi Dott.ssa P. Bertolini
0319	PAVIA Clinica Pediatrica Policlinico “S.Matteo” P.le Golgi 2 27100 PAVIA Tel. 0382/502770-557-629 Fax 0382/527976 e-mail: gl.marseglia@smatteo.pv.it r.maccario@smatteo.pv.it	Prof. G. Rondini Prof.. GL. Marseglia Prof.ssa R.Maccario Dott.ssa G. Bossi
0303	PAVIA Oncoematologia Pediatrica IRCCS, Policlinico San Matteo P.le Golgi 2 27100 PAVIA Tel.0382/502607 Fax 0382/501251 e-mail: f.locatelli@smatteo.pv.it	Dott. F. Locatelli Dott. M. Zecca
0903	PESARO U.O. Pediatria Neonatologia Az. Ospedaliera San Salvatore P.le Cinelli 4 61100 PESARO Tel. 0721/362310 Fax 0721/362311 e-mail: pediatria.ps@abanet.it	Dott. L. Felici
0703	PISA Clinica Pediatrica III Via Roma 66 56100 PISA Tel. 050/992840-2222 Fax 050/888622 e-mail: p.macchia@clp.med.unipi.it rita.consolini@clp.med.unipi.it	Prof. P. Macchia Dott.ssa R. Consolini Dott. C. Favre
0607	RIMINI Divisione Pediatria Ospedale “Infermi” Via Settembrini 11	Prof. V. Vecchi Dott.ssa P. Sacchini Dott.ssa G. Rinaldi

	47900 RIMINI Tel. 0541/705210 Fax 0541/705360	
1110	ROMA Div.ne di Immunoinfettivologia Ospedale Bambino Gesù P.zza S. Onofrio 4 00165 ROMA Tel. 06/68592508 Fax 06/68592508 e-mail: ugazio@opbg.net rossi@opbg.net livadiotti@opbg.net	Prof. A.G. Ugazio Prof. P. Rossi Dr.ssa Livadiotti
1107	ROMA Clinica Pediatrica Università Cattolica Sacro Cuore Largo Gemelli 8 00135 ROMA Tel. 06/30514348-4290 Fax 06/3051343 e-mail: iclpe@RM.unicatt.it	Prof. A. Stabile
1108	ROMA Ist. Clinica Pediatrica Università "La Sapienza" Viale Regina Elena 325 00163 ROMA Tel. 06/4404994 e-mail: margherita.bonamico@uniroma1.it giovanni.nigro@uniroma1.it	Dott. G.Nigro Prof.M.Bonamico
1109	ROMA Dipart. Medicina Clinica Università "La Sapienza" Viale dell'Università 37 00186 ROMA Tel. 06/49972036 Fax 06/49972037 e-mail: quinti@uniroma1.it	Prof.ssa I. Quinti Dr.ssa V. Guazzi
1111	ROMA Centro Interdisciplinare Pediatria Policlinico Tor Vergata Univ. Tor Vergata Viale Oxford 81 00133 ROMA tel.06/20900529 fax 06/20900530 e-mail:moschese@med.uniroma2.it	Prof. P.Rossi Prof. V.Moschese
0702	SIENA Dipart. Di Pediatria Univ. di Siena V.le Bracci 16 53100 SIENA tel. 0577/263415 fax 0577/263415 e-mail:pediatria@unisi.it	Prof. G. Morgese Dott. Acquaviva
0313	TREVIGLIO(BG) Div. di Pediatria Ospedale di Treviglio P.zza Ospedale 1 24047 TREVIGLIO (BG) Tel. 0363/424273 Fax 0363/424400	Dott. L. Re Dott. R. Cogliati
0408	TREVISO Div. Pediatrica Osped. Regionale Treviso Via Ospedale 7 31100 TREVISO Tel. 0422/322266 Fax 0422/322232 e-mail: gdezan@ulss.tv.it	Dott. G. De Zan Dott.ssa S.Strafella

Code	Centre	Contacts
0501	TRIESTE Clinica Pediatrica Ospedale Infantile “Burlo Garofolo” Via dell’Istria 65/I 34137 TRIESTE Tel. 040/3785342 Fax 040/3785494 e-mail: tamaro@burlo.trieste.it rabusin@burlo.trieste.it	Prof. P. Tamaro Dott. M. Rabusin
0105	TORINO Dip. Scienze Ped. e dell’Adolescenza Osp. Infantile Regina Margherita P.zza Polonia 94 10126 TORINO Tel. 011/3135798 Fax 011/ 3135517 e-mail: tovo@pediatria.unito.it silvana.martino@unito.it	Prof. PA. Tovo Dott.ssa S. Martino
0309	VARESE Clinica Pediatrica Università di Pavia Ospedale “F. Del Ponte” P.zza Biroldi 1 21100 VARESE Tel. 0332/285300- 299231-299390 Fax 0332/235904	Prof. L. Nespoli Dott.ssa M. Marinoni
0405	VENEZIA Dipart. Oncologia ed Ematologia Oncologica Ospedale P.F. Calvi Largo S. Giorgio 2 NOALE (VE) Tel. 041/5896221 Fax 041/5896259 e-mail: emanoale@tin.it	Prof. A. Porcellini
0409	VERONA Centro Fibrosi Cistica Ospedale Civile di Verona P.le Stefani 1 37126 VERONA Tel. 045/8072294 FAX 045/8072042 e-mail: giantonio.cazzola@mail.azosp.vr.it	Dott. GA. Cazzola

INDEX

1. INTRODUCTION page 12
1.1 What is Chronic Granulomatous Disease?
1.2 Biochemistry and genetics of CGD
1.3 Molecular biology of CGD
1.3.1 X-linked CGD
1.3.2 Autosomal recessive CGD
1.3.3 Genotype-phenotype correlation
1.4 What are the symptoms of CGD?
1.5 Complications
1.6 Diagnostic criteria for CGD

2. DIAGNOSTIC PROTOCOL page 20
2.1 Diagnosis
2.2 Sending samples
2.3 Inclusion criteria
2.4 Genetic typing

3. TREATMENT RECOMMENDATIONS page 23
3.1 Drug management
3.2 How patients can help prevent infections
3.3 Vaccinations
3.4 Tests at onset and during follow-up
3.5 Bone marrow transplantation

4. TREATMENT OF INFECTIONS page 26
4.1 Tests to be done at every infectious episode
4.2 Fungal infections
4.3 Treatment of infectious complications
4.3.1 Staphylococcus Aureus lymphadenitis
4.3.2 Staphylococcus Aureus liver abscess
4.3.3 Burkolderia Cepacia pneumonia
4.4 Complementary treatments
4.4.1 Corticosteroids
4.4.2 Transfusion of granulocyte concentrates
4.4.3 G-CSF
4.4.4 Gene therapy

5 PREVENTION page 33
5.1 How to identify disease carrier status
5.2 Prenatal diagnosis

6 REFERENCES page 34

AIM

The recommendations for the diagnosis and treatment of Chronic Granulomatous Disease (CGD) have been devised to optimize the approach to the diagnosis and treatment of “orphan diseases” like primary immunodeficiencies.

Establishing nationwide diagnostic and therapeutic recommendations and analysing patient outcome will allow ongoing adjustments and updates designed to offer all patients high uniform standards of care.

The aim of these recommendations is to:

- Establish standard diagnostic criteria;
- Define updated therapeutic recommendations to be applied nationwide for all CGD patients;
- Record the natural history and any complications of the disease as well as any side effects of treatment;
- Adjust treatment protocols on the basis of the outcome of any controlled experimental trials and results obtained by other research groups.

The first part of these diagnostic and therapeutic recommendations presents the clinical and pathogenetic state-of-the-art of CGD. The second part outlines the diagnostic and therapeutic recommendations; *basic indications are in italics*. The third part offer suggestions for the management of infections and complications in CGD patients. The fourth and last part deals with disease prevention from a genetic standpoint. The last two sections are not part of the diagnostic and therapeutic protocol as such, but updated information on the clinical, diagnostic and therapeutic aspects of CGD.

1. INTRODUCTION

1.1 What is Chronic Granulomatous Disease?

Chronic Granulomatous Disease (CGD) was described for the first time by both B.H. Landing and R.A. Good in 1957. CGD comprises a rare group of genetically determined changes affecting the immune system characterized by the inability of the body's phagocytic cells (neutrophil and monocyte granulocytes) to kill certain phagocytosed microorganisms. This phagocytic cell defect is caused by mutations in the gene coding for the NADPH oxidase enzyme essential for the microbicide activity of phagocytic cells.

The disease affects an average of one in every 250,000 live births. Affected children are subject to frequent severe bacterial and fungal infections with the granulomatous hallmark of inflammatory lesions in histological specimens from which the name CGD derives.

1.2 Biochemistry and genetics of CGD

Under normal conditions, exposure of phagocytes to opsonized germs results in prompt metabolic activation, namely the hexose monophosphatase shunt accompanying an up to 100-fold increase in oxygen and glucose consumption known as the "respiratory burst".

A key role in the respiratory burst is played by the nicotinamide-adenine-dinucleotide-phosphate oxidase (NADPH oxidase) system. This enzyme is a membrane flavoprotein transferring electrons from NADPH oxidase to molecular oxygen (O_2) with the formation of the superoxide ion (O_2^-), which is then transformed into hydrogen peroxide (H_2O_2) and hypochlorous acid (HOCl) within the phagosome by superoxide dismutase and lysosomial myeloperoxidase. The killing of phagocytosed microorganisms is linked to the production of these reactive oxygen products which damage the bacterial membrane.

The NADPH oxidase complex is composed of four subunits: two molecules, p22 *phox* (alpha subunit) and gp9l *phox* (beta subunit) forming the complex known as cytochrome *b558,* constitutively present on the cell membrane and on that of specific granules and secretory vesicles of the neutrophil granulocyte. This complex contains two haeme groups and two phagosome groups required to transport electrons from cytoplasmic NADPH to the O_2 contained in the phagosome. Another two proteins, weighing 47 and 67 kDa respectively, are present exclusively in the cytoplasm. A third protein, p40 phox, is found in the cytosol and seems to be involved in stabilizing the p47/p67 phox complex in resting phagocytes. After cell activation induced by a series of stimuli (microorganisms or opsonized bacterial peptides, complement C5a fraction, etc.) the secretory vesicles merge with the phagocyte plasma membrane thereby leading to the passage of cytochrome b 558 on the phagocytic cell membrane. At the same time, the phosphorylated cytosolic proteins p47 and p67 phox shift onto the plasma membrane where they interact with the b558 complex completing the assembly of the NADPH enzyme complex able to carry out its full oxidase activity.

Other low molecular weight GTP-binding proteins belonging to the *rac* family are involved in the translocation process*:* in particular *rac 1*, which binds to the p47, p67 and p40 phox cytosol protein complex. Another low molecular weight protein *rap* 1 A, associated with cytochrome b 558 and localized on the granule and secretory vesicle membrane, is involved in oxidase regulation.

In CGD one of the proteins belonging to the NADPH oxidase system is missing, reduced or functionally impaired. This means that phagocytosis occurs normally but the phagocyte is unable to process oxygen to produce the toxic metabolites needed for killing. As a result, the phagocytosed microorganisms survive within the cells and antibodies and most antibiotics have difficulty reaching them. CGD may be caused by a defect in any of the four protein subunits and this accounts for the genotypic heterogeneity of the disease (Table 1).

In 60% of cases CGD is caused by a mutation in the gene coding for the gp91 *phox* subunit located on the short arm of chromosome X (Xp21.1). Autosomal recessive variants are caused by mutations in the gene coding for the p22 phox subunit mapping to the long arm of chromosome 16 (16q24). Around 5% of cases depend on the genes for p47 phox or p67 phox respectively mapping to the long arm of chromosome 7 (7q11.23) and the short arm of chromosome 1 (1q25) and representing 25% and 5% of all cases of CGD. The mutations involving p40 phox are not known.
In addition, there are variants (+) and (–) for each of the protein subunits gp91 and p22 phox caused by mutations which leave the protein intact but abolish its enzymatic activity (+) or attenuate protein expression with residual functional activity (-).

Table 1: Classification of Chronic Granulomatous Disease

Impaired protein	Chromosome	Gene locus	Inheritance pattern	Subtype[a] (%)	NBT (% positive cells)	O_2^- Production (%)	Cyt. b (%)	Frequency of cases (%)
Gp91 phox	Xp21.1	CYBB	XR	$X91^0$	0	0	0	55-60
				$X91^-$	80-100 (weak)	3-30	3-30	5
				$X91^+$	0	0	100	1-3
P22phox	16p24	CYBA	AR	$A22^0$	0	0	0	~ 5
				$A22^+$	0	0	100	~ 1
P47phox	7q11.23	NCF1	AR	$A47^0$	0	0	100	25
P67phox	1q25	NCF2	AR	$A67^0$	0	0	100	5

(Modified from J.T Curnutte, Immunodef. Rev 1992; 3: 149)

[a] indicates protein expression is normal (+), reduced (-) or absent (0).

1.3 Molecular biology of CGD

1.3.1 X-linked CGD

With the exception of gene conversion, all of the more than 60 mutations in CGD have been identified in the CYBB gene. Deletions and insertions in this gene are present in 35% of XCGD patients, whereas single nucleotide substitutions have been disclosed in the remaining 65%. Nucleotide substitutions include mutations in the splicing site (16%), missense mutations (23%) causing a single aminoacid substitution which may lead to the formation of an inactive gp91 protein, and nonsense mutations resulting in premature termination of protein synthesis (27%). When gene deletions are large, genes adjacent to the CYBB gene may also be affected so that patients will have other clinical disorders like Duchenne's muscular dystrophy, retinitis pigmentosa and McLeod's syndrome: haemolytic anaemia with acanthocytosis due to deletion of the gene coding for a 37 Kda erythrocyte protein required for the expression of Kell antigens.

1.3.2 Autosomal recessive CGD

Fewer mutations have been identified in the autosomal recessive form of CGD. They include insertions, deletions, missense and splicing site mutations. The heterogeneity of the molecular defect of the A67 form is greater than that of A47 CGD which is almost always caused by a GT (guanine-thymidine) deletion in exon 2 due to recombination events between the p47 phox gene and one or more closely linked pseudogenes.

1.3.3 Genotype-phenotype correlation

Patients with X-linked CGD tend to have a more severe clinical disease course than those with the autosomal recessive form due to persistent residual NADPH oxidase activity in the neutrophils of $A47^0$ and $A67^0$ patients. This suggests that the b558 membrane complex plays a more critical role than cytosolic proteins in the oxidative process. XCGD patients with $X91^0$ and $X91^+$ phenotype should be distinguished from those with the $X91^-$ phenotype. Patients with the $X91^-$ phenotype have 10-30% residual oxidase activity and therefore tend to have a better clinical course, but this is not always the case because oxygen independent auxiliary antimicrobial systems probably enter into play. Generally speaking, insertions, nonsense and splicing site mutations lead to an $X91^0$ phenotype, whereas missense mutations are responsible for all three phenotypes.

In addition, a third of the X-linked forms of CGD are caused by *de novo* gene mutations in which the results of biochemical tests and molecular gene analysis are normal even in presumed disease carriers. Instead, obligate CGD carriers occasionally present clinical manifestations similar to those of hemizygote patients. This is usually the result of extreme lyonization when carrier females have fewer than 10% normal phagocytes and always present missense mutations.

1.4 What are the symptoms of CGD?

Two thirds of patients with CGD develop the signs of disease within the first two years of life with a wide range of clinical manifestations. The onset of X-linked CGD is usually earlier than that of autosomal recessive CGD which may even present in adulthood. Any organ may be affected, but the usual sites of infections are the lungs, lymph nodes, and skin (Tables 2 and 3).

Table 2: Common sites of infection in Chronic Granulomatous Disease

Very common (> 60%)	**Common (20-60%)**	**Sporadic (< 20%)**
Lungs	Middle ear	Paranasal sinuses
Lymph nodes	Bones	Hearing apparatus
Skin	Perirectal region	Central nervous system and meninges
	Systemic (septicaemia)	Pericardium

Table 3

CGD : clinical manifestations	**% cases**
Purulent dermatitis	60-70
Middle ear otitis	15-20
Conjunctivitis	10-20
Sinusitis	<10
Ulcerative stomatitis	5-25
Pneumonia	70-80
Bowel infections	5-15
Abscesses/ perirectal fistulae	15-30
Urinary tract infections	5-15
Lymphadenopathy	98
Lymphadenitis	60-80
Hepatosplenomegaly	50-90
Liver/perihepatic abscesses	30-40
Sepsis	10-20
Osteomyelitis	20-30
Kidney/perirenal abscesses	<10
Meningitis	<5
Brain abscesses	<5
Pericarditis	<5
Chorioretinitis	<10
Gengivitis	50
Pulmonary fibrosis	<10
Oesophagitis	<10
Gastric antrum stenosis	<10
Ileocolic granulomatosis	<10
Glomerulonephritis	<10
Hydronephrosis	10-25
Granulomatous cystitis	<10
Anaemia	Common
Hypergammaglobulinaemia	60-90
Weight Deficit	70
Failure to thrive	50
Delayed wound healing	Common
Discoid lupus erythematosus	Rare
McLeod’s syndrome	Extremely rare

The hallmarks of CGD are recurrent infections, unusual etiologic agents and the granulomatous evolution of inflammatory lesions. These granulomata, made up of giant cells and macrophages full of lipids, destroy the parenchyma and result in frequent stenosis of the gastrointestinal or urinary tracts and require surgical removal.

The dissemination of infection is facilitated by the fact that microoorganisms phagocytosed but not killed by leucocytes in the site of primary infection can be transported to distant sites to then involve the kidneys, muscles, pericardium, CNS and other organs.

Although many of the clinical manifestations of CGD are aspecific, infections caused by Aspergillus, recurrent pyodermitis, granulomatous liver abscess, atypical forms of tuberculosis and osteomyelitis of the metatarsal bones resistant to treatment may provide a valuable clue to the diagnosis (Table 4).

Patients may also present associated illnesses like lymphadenopathy, hepatosplenomegaly, malabsorption, hydronephrosis, failure to thrive and microcytic anaemia caused by chronic disease which usually resolves spontaneously at the end of the first decade of life.

The commonest microbial species include: catalase positive germs which breakdown the H_2O_2 they produce, *Staphylococcus aureus, Escherichia Coli, Salmonella, Klebsiella,* various strains of *Pseudomonas,* saprophytic bacteria like *Serratia marcescens, Staphylococcus epidermidis, Enterobacter, Burkholderia Cepacia,* and fungi like *Aspergillus* and *Candida* (Table 5).

Table 4: Valuable clues to the diagnosis of Chronic Granulomatous Disease.

Aspergillus infection at any age
Serratia infection at any age
Osteomyelitis
Lymphadenitis caused by Staphylococcus
Liver abscess
Granulomatous colitis
Obstruction of the airways and/or digestive and/or urinary tracts by granulomatous inflammation

Table 5: Spectrum of infectious agents in CGD

MICROORGANISMS	% isolates
Gram + bacteria	**~ 40**
Staphylococcus aureus	30-50
Staphylococcus epidermidis	5
Streptococcus	4
Nocardia	2
Actinomyces	<1
Gram - bacteria	**~ 40**
Escherichia Coli	5-10
Klebsiella	5-10
Salmonella	5-10
Serratia marcescens	5-10
Enterobacter	3
Proteus	3
Burkholderia cepacia	5-10
Chromobacterium violaceum	<1
Francisella philomiragia	<1
Fungi	**~ 20**
Aspergillus	10-20
Scedosporium	?
Candida albicans	3
Torulopsis	<1
Other	
BCG	<1
Mycobacterium fortuitum	<1
Pneumocystis carinii	<1

CGD carriers are usually asymptomatic with some major exceptions: around half of the X-linked carriers have recurrent stomatitis and gingivitis, while a quarter develop discoid lupus erythematosis on the skin of the face, shoulders, arms and back, probably linked to antibodies against microbial antigen fractions. These lesions do not usually progress towards a systemic form of CGD.

1.5 Complications

Complications are caused by the mechanical obstruction ensuing from the typically granulomatous evolutions of inflammatory lesions mainly affecting the gastrointestinal and urinary apparatus and resulting in pyloric stenosis, chronic bowel inflammation, hydronephrosis, urethral stenosis and granulomatous cystitis.

1.6 Diagnostic criteria for CGD (established by ESID and PAGID, 1999)

Certain diagnosis**:**
Male or female with abnormal NBT or unchanged "respiratory burst" in activated neutrophils (less than 5% of control) with one of the following:

1) Mutation in gp91, p22, p47, p67 phox
2) Absent mRNA for one of the above genes by Northern Blot analysis.
3) Maternal cousins, uncles or nephews with an abnormal NBT or respiratory burst

Probable Diagnosis**:**
Male or female with abnormal NBT or unchanged "respiratory burst" in activated neutrophils (less than 5% of control) with one of the following:

1) Liver, perirectal or lung abscess, adenitis or osteomyelitis due to Staphylococcus, Serratia marcescens, Candida or Aspergillus.
2) Diffuse granulomata I respiratory, gastrointestinal or urinary tracts
3) Failure to thrive and hepatosplenomegaly or lymphadenopathy.

Differential diagnosis:

1) Leucocyte adhesion deficit (LAD)
2) Sarcoidosis
3) Hyper-IgE

2. DIAGNOSTIC PROTOCOL

2.1 Diagnosis

When Chronic Granulomatous Disease is suspected diagnosis is made by establishing impaired granulocyte activity using one of the following tests:

- ***Nitro-blue tetrazolium test (NBT)*** *is a semiquantitative test. Under normal conditions, NBT is yellow and soluble in the presence of superoxide and is reduced to formazan, a dark blue insoluble reagent precipitated in phagocytic cells previously activated with phorbol myristate acetate (PMA), with particles opsonized with zymosan (OPZ) or N-formyl-methionyl-leucyl-phenylalanine (fMLP). In a CGD patient the superoxide is not formed and therefore NBT is not reduced to formazan.*

- ***Flow cytometric analysis by dihydrorodamine 123 (DHR)*** *is a quantitative test based on the use of DHR as a fluorescent marker of oxidase activity. In many laboratories this test has replaced NBT as it is highly sensitive and can be performed on whole blood up to 24 h after sampling.*

- ***CYTOCHROME "C"*** *is a quantitative test based on the reduction of C ferricytochrome by the superoxidase produced by PMA-stimulated neutrophils and monocytes. The drop in C ferricytochrome is measured by spectrophotometry at 550 nm.*

- ***Chemiluminescence*** *is a quantitative test based on the ability of stimulated phagocytes to interact with oxidizable substrate. On return to the baseline energy state the phagocytes emit light which is measured by a liquid phase beta scintillator.*

Which test is chosen will depend on the experience of the centre dealing with CGD patients which will already have developed a reliable diagnostic test.
Hospitals lacking a specialized laboratory for the diagnosis of CGD can refer to one of the Italian laboratories listed below for CGD testing of blood samples. These laboratories use flow cytometric analysis by dihydrorodamine 123 for CGD diagnosis.

2.2 Sending samples

After the meeting on 14th December 2000, the centres available to carry out dihydrorodamine 123 for CGD diagnosis were contacted and five are already using the test on a routine basis and are prepared to act as national reference centres. Blood samples from CGD patients, their mothers and normal subjects were sent at room temperature by a courier guaranteeing delivery within 24h to ascertain the reproducibility of results.
The results were reproducible and reliable for the diagnosis of CGD but not for the identification of carrier status. For this reason, blood samples can be sent to these centres below for diagnosis of CGD, whereas the diagnosis of carrier status must await the outcome of further standardization tests to be carried out in the near future.
Centres opting to undertake the identification of carrier status by this method are free to do so outside these recommendations.

BARI

Prof. D. De Mattia
Dipart. Biomedicina dell'Età Evolutiva
Clinica Pediatrica I
P.zza G. Cesare 11
70124 BARI
Tel. 080/5478906
Fax 080/5592290
e-mail: demattia@bioetaev.uniba.it

BRESCIA

Prof. A. Plebani
Clinica Pediatrica
Spedali Civili
P.le Spedali Civili,1
25123 BRESCIA
Tel. 030/3995715
Fax 030/3388099
e-mail: plebani@master.cci.unibs.it

FLORENCE

Cr. C. Azzari
Dipart. di Pediatria
Ospedale "A. Meyer"
Via L. Giordano, 13
50132 FIRENZE
Tel. 055/5662416
Fax 055/570380
e-mail: ematoncped@cesit1.unifi.it

NAPLES

Prof. C. Pignata
Unità Specialistica di Immunologia
Dipart. di Pediatria
Univ. Studi di Napoli "Federico II"
Via Pansini 5
80131 NAPOLI
Tel. 081/7464340
Fax 081/5451278
e-mail: pignata@unina.it

ROME

Prof. P. Rossi
Dott.ssa S. Di Cesare
Laboratorio Immunologia
e Biotecnologie molecolari
Dipartimento Sanità Pubblica
e Biologia cellulare
Università Tor vergata
Torre E Nord, sesto piano
Via di Tor Vergata,135
00133 ROMA
Tel. 06/72596825
e-mail: rossi@opbg.net

ROME

Dr. I. Quinti
Dr. Iacobini
Dipart. Medicina Clinica
Università "La Sapienza"
Viale dell'Università 37
00186 ROMA
Tel. 06/49972036
Fax 06/49972037
e-mail: quinti@uniroma1.it

Telephone arrangements should be made for sending blood samples to one of the approved centres to carry out flow cytometric analysis by dihydrorodamine 123 for CGD diagnosis.

The following must be sent for this test:

- *A test tube containing 7 cc heparinized blood per patient. A test tube containing 7 cc heparinized blood from a normal subject should also be sent as an internal control.*

- *Samples also be accompanied by Form A duly compiled and sent the TRACO 10 service which guarantees delivery of samples by 10 a.m. on the following day. Please note that samples must be analyzed immediately to ensure reliable results.*

- *The doctor requesting the test will be notified of the results in writing (fax or e-mail) within 48 hours.*

2.3 Inclusion criteria

Diagnosis of CGD is made in male and female subjects with impaired granulocyte metabolism disclosed by one of the tests listed above.
*A registration form (**Form 1.03**) and a diagnosis form (**Form 22.01**) will be filled in for patients meeting these inclusion criteria. Annual follow-up forms (**Form 22.02**) will then be filled in and sent to the AIEOP Operation Office in Bologna.*

2.4 Genetic typing

No gene mutation analysis is planned for the first year.

3. TREATMENT RECOMMENDATIONS

Once a diagnosis of CGD has been established, the first mainstay of treatment is the prevention of infections by the following measures:
1) Drug management
2) Helping to prevent infections
3) Vaccinations

3.1 Drug management

Therapy is aimed at preventing bacterial and fungal infections with the following drugs:

Co-trimoxazole: 6-8 mg/Kg/die trimethoprim per os once or twice daily up to a maximum of 160 mg trimethoprim a day. In the case of sulphonamide allergy dicloxacillin can be given at a dose of 25-50 mg/Kg/die per os, in 4 divided doses. Co-trimoxazole is contraindicated in patients with a G6PD deficiency.

Itraconazole: 10 mg/Kg die per os once daily (up to a maximum dose of 200 mg/die)

Interferon γ: 50 μg /m² in patients with a body surface area of > 0.5 m²; 1.5 mcg/kg/dose in patients with a body surface area of <0.5 m². The drug is administered by subcutaneous injection three times a week (e.g. Monday, Wednesday, Friday).

- *Side effects: fever, headache, chills, myalgia, fatigue, nausea, vomiting and rashes.*
- *These effects are usually well-controlled by premedication with paracetamol (10-15 mg/kg/dose per os, 30-60 minutes before drug administration) or nimesulide at a dose of 2 mg/Kg up to a maximum of 100 mg. Nimesulide is not recommended for children under 12 years.*
  In some patients interferon γ can give rise to autoantibodies, rheumatoid factor, development of LES, leucopenia and thrombocytopenia.
- *Contraindications to the use of interferon γ: autoimmune disease, depressive syndromes.*

3.2 How patients can help prevent infections

The following lifestyle recommendations are very important for the prevention of infections:

▪Thorough personal hygiene; use mild soap; brush teeth twice daily with hydrogen peroxide and bicarbonate toothpaste; use mouthwash to reduce the likelihood of gingivitis.
▪Avoid alcohol and smoking (tobacco contains Aspergillus).
▪Prevent constipation.
▪Avoid granaries, caves and other dusty or damp areas (Aspergillus).
▪To avoid inhaling large amounts of fungi do not work in environments with mould, hay, wood chippings, compost or other rotten or fungi infested grass or wood.
▪Antibiotics should be taken before and after any dental treatment.
▪Any cut or graze should be washed thoroughly with soap and water then disinfected and rinsed with hydrogen peroxide; patients are urged to consult their physicians promptly if any rash or irritation around the lesion site, presence of pus or fever.
▪Walking barefoot is not recommended.
▪Do not use wood chip playing fields but those with a smooth or gravel surface.
▪Wear an air filter mask for gardening.
▪Avoid planting houseplants as mould often grows in the earth.
▪Add a teaspoon of bleach to vases of fresh flowers to reduced the formation of mould and algae.
▪Avoid living in old buildings or newly built or refurbished buildings before they have been thoroughly cleaned.
▪Do not lift or move carpets or tiles; thoroughly clean rooms before use.
▪Pets are tolerated but avoid using sawdust for litter; make sure pets are vaccinated regularly; keep water bowl and litter clean.
▪Empty vaporizers daily and wash with bleach to avoid mould.
▪Patients are urged to consult their physicians promptly in case of fever especially when accompanied by cough.

3.3 Vaccinations

Chronic granulomatous disease is not a contraindication to the administration of the regular scheduled vaccinations. CGD patients should also have annual anti-influenza, anti-pneumococcal and anti-meningococcal vaccinations.

3.4 Tests at diagnosis and during follow-up:

Every 6 months:

- Full blood count
- Transaminase levels
- Azotaemia, creatininaemia
- ESR. PCR
- FAN
- Anti-aspergillus antibodies (with titre)

Every year:
To monitor any organ specific damage:
X-ray
Ultrasound scan
CT and/or MR scan
Spirometric tests

Every 2 years:
High resolution lung CT scan

3.5. Bone marrow transplantation

Conventional treatment has the following limitations:
- poor lifetime compliance with prophylaxis against infections;
- difficulty in preventing the inflammatory sequelae of infections;
- impaired quality of life due to frequent hospital admissions and permanent organ damage.

Around 30% of patients die from infectious complications.
Bone marrow transplant is currently the only possible cure for CGD and should be entertained especially for patients with X-linked CGD at the time of diagnosis whenever an HLA-identical family donor is available.

4. TREATMENT OF INFECTIONS

•Each infectious episode is potentially dangerous so every effort must be made to isolate the microorganism responsible, focusing on Aspergillus.
•Every episode of fever must be treated promptly by an aggressive use of drugs able to cross the phagocyte cell membrane and accumulate within the phagocytic cells (see Table 6).
•Initial empirical therapy should include at least two antibiotics against Gram+ and Gram- bacteria (see Table 7).
•Treatment should be continued for weeks or months even when there is a significant improvement in the inflammatory index and the patient's clinical conditions to eradicate the infection completely.

Table 6: Relation between intra (I) and extra (E)-cellular concentration of antibiotics in neutrophil PMN

ANTIBIOTIC	I/E in PMN
Penicillin G	0.4
Gentamicin	1
Isionazid	1.5
Phosphomycin	2
Cloramphenicol	2.6
Trimethoprim	4
Clindamycin	11
Erythromicin	13.3
Rifampicin	14
Azithromycin	40
Teicoplanin	60

(modified from: Il Bambino Immunodepresso, A.Ugazio et al.)

Drugs against Gram+ bacteria (e.g.. Staphylococcus aureus):
Teicoplanin: 6 mg/kg by intravenous injection every 12 hours for the first 2 days (attack dose), continue with the same dose once daily. Side effects: mild hearing loss, appearance of Factor VIII antibodies has been reported.
Clarythromicin: 15 mg/kg/die by intravenous injection twice daily. Side effects: gastrointestinal disorders and hepatic impairment.
Rifampicin : 20 mg/kg/die in a single intravenous injection. Do not exceed the maximum dose of 600 mg/die. Monitor liver function for possible hepatic impairment.
Drugs against Gram- bacteria
Phosphomycin: 200 mg/kg/die by intravenous injection 3-4 times daily.
Ciprofloxacin: 15 mg/kg/die by intravenous injection twice daily. This drug is a quinolone and may damage the tendons and weight-bearing joints in children. Treatment should be discontinued in case of pain and/or oedema in the Achilles' tendon (possible rupture) or persistent severe diarrhoea (possible onset of pseudomembranous colitis).

Table 7: Treatment of infections

Treatment	Indications	Duration	Drug	Dose
Antibiotics	Gram+ infections	Months	Rifampicin Clarithromycin	20 mg/kg/die 15 mg/kg/die
	Gram– infections	Months	Ciprofloxacin Phosphomycin	15 mg/kg/die 200 mg/kg/die
	Fungal infections	At least 6 months	Liposomial amphotericin B	1-3 mg/kg/die
Transfusion of granulocytes	Resistant infections	Until resolution	Leucocytes stimulated with G-CSF+ dexamethasone	1 Unit / 10 Kg
Anti-inflammatory treatment	Obstructing granulomata	7-10 days→tapered	Prednisone	0.5-1 mg/kg/die

4.1 Tests to be done at every infectious episode

1. Inflammatory indices: blood cytochrometric test, ESR, PCR, serum immunoglobulins. Neutrophil leucocytosis, raised ESR, PCR and hypergammaglobulinaemia are also markers for monitoring infection and response to treatment.
2. Culture tests: blood, urine, faeces, culture from infected sites, culture of exudates or transudates, sputum or broncheoalveolar lavage.

N.B. Culture tests must also be accompanied by the request for an antibiogram.

3.
4. Diagnostic imaging: X-ray, ultrasound, CT, MR scans,.

In case of lymphadenitis and/or liver abscess an echo-guided needle aspirate should be performed. Biopsy may sometimes be necessary for accurate identification of the etiologic agent.

4.2 Fungal infections

Aspergillus infection is the most serious infectious event and the prime cause of death in CGD patients. The microorganisms most commonly involved are *Aspergillus Fumigatus* and *Aspergillus Flavus*, but other species may also give rise to Aspergillosis.
The organs most frequently affected are lungs, bones, muscles and brain. Diagnosis is based on:

1. Clinical and radiological evidence of infection.
2. Isolation and identification of the Aspergillus on culture specimens (expectorate, broncheoalveolar lavage); blood culture is seldom positive even in the course of disseminated Aspergillosis.
3. Biopsy of the affected organ is often required for diagnosis.
4. Search for anti-Aspergillus IgM and IgG antibodies by immunofluorescence, immunodiffusion or ELISA. Other techniques have now been developed to search for the antigen by immunoblotting, ELISA, radioimmunologic tests and PCR, but are only available in highly specialised laboratories.

If a fungal infection is identified or strongly suspected, treatment includes:

Amphotericin B
This drug is used for systemic fungal infections and is active against *Candida* and *Aspergillus* binding to ergosterol, a protein in the fungal cell wall, causing its rupture and hence cell lysis.
Preparation of the infusion: the vial containing 50 mg Amphotericin B must be dissolved in 10 ml sterile distilled water, shaking until a clear solution is obtained; the solution must be further dissolved in 490 ml dextrose at 5% with pH > 4.2 to obtain an Amphotericin B concentration equal to 0.1 mg/ml. The infusion solution must be prepared until rigorously sterile conditions.
Dose:
Day 1: test dose of 0.25 mg
Day 2: 0.25 mg/Kg/die
Day 3: 0.5 mg/Kg/die
Day 4: 0.75 mg/Kg/die
Day 5 onwards: 1 mg/Kg/die.

The solution should be administered slowly by intravenous infusion lasting from 2 to 6 hours and the solution kept out of the light during infusion.

Treatment must be prolonged for months and can be administered on alternate days after 4-6 weeks; shorter treatment may give rise to relapse.

Amphotericin B does not cross the blood brain barrier making intrathecal administration necessary if the fungal infection involves the central nervous system: the Amphotericin B solution is prepared as above (at a concentration of 0.1 mg/ml) diluted 1:10 in 10% glucosate solution. At this concentration (0.01 mg/ml) the drug can be administered by intraspinal infusion twice weekly as follows:
Day 1: 0.025 mg
Day 2: 0.05 mg
Day 3: 0.075 mg
Day 4: 0.1 mg
If necessary continue with:
Day 5:0.25 mg
Day 6: 0.5 mg (maximum dose)
Interactions: Amphotericin B synergy increases cellular uptake of flucytosine so that the doses of Amphotericin B can be reduced thereby attenuating its toxicity.
Corticosteroids when given with Amphotericin B carry an increased risk of hypokalaemia. In addition, acute pulmonary reactions have been reported when Amphotericin B was administered during or just after leucocyte transfusions. For this reason it is recommended that these infusions be given separately monitoring lung function.
Side effects:
-early: general reactions (febrile reactions, nausea, vomiting, muscle and joint pain, epigastric pain), local reactions (thrombophlebitis at the injection site).
-late: varying degrees of renal toxicity with possible renal tubular acidosis and hypokalaemia, convulsions, arrythmias, hypo and hypertension, blood dyscrasias, abnormal liver function.
Treatment of adverse reactions:
Early side-effects can be minimized by

1) reducing the infusion speed
2) administering small doses of heparin to minimize thrombophlebitis
3) administering salicylates (20 mg/Kg) or hydrocortisone (10 mg/Kg) before Amphotericin B infusion.

Amphotericin B induced hypokalaemia can be prevented by good hydration and oral or parenteral administration of potassium salts 2 mEq/Kg/die.
Tests to be done during treatment: renal function indices, serum electrolytes, urine test and full blood count.
The drug's high toxicity sometimes prevents its administration. In these cases lipid formulations of Amphotericin B are recommended as they are significantly less toxic.

Amphotericin B lipid formulations (Ambisome, Amphocil 50: vial 50 mg)
With respect to Amphotericin B, the uptake of lipid formulations by liver and spleen is greater than that in the kidneys and lungs. Lipid formulations are also less toxic and have better tissue penetration thanks to ingestion by macrophages.
Dose: 1-3 mg/kg/die single intravenous infusion for at least 3 months after which treatment can be discontinued on alternate days followed by Itraconazole for life.
Preparation:

1. add 12 ml sterile water to the vial to obtain and injection solution containing 4mg/ml Amphotericin.
2. use the 5 micron filter supplied to dilute the total infusion amount with 5% dextrose to obtain a dilution of 0.5 mg/ml Amphotericin.
3. Infuse intravenously over 30-60 minutes.

The drug is usually well tolerated and does not give rise to major side effects. Diuresis and renal function should be monitored during treatment.

Voriconazole: (UK-109,496) (Pfizer Central Research, Sandwich, England)
This drug can be given as an alternative if response to Amphotericin and its lipid formulations is poor. Voriconazole is a new broad spectrum triazolic molecule active against fungal infections caused by *Aspergillus*, *Candida Krusei* and *Candida glabrata* and has been successfully used as an adjunct to treat invasive Aspergellosis in patients with AIDS and CGD. However, its efficacy and long-term safety have yet to be assessed in controlled clinical trials.

4.3 Treatment of infectious complications

4.3.1 <u>Lymphadenitis due to Staphylococcus aureus</u>

- Incision/ Drainage
- Rifampicin and Teicoplanin at the doses indicated above.
- If treatment fails: exeresis

4.3.2 Liver abscess due to Staphylococcus aureus

- Echo-guided needle aspiration;
- Rifampicin and Teicoplanin for months;
- If treatment fails: Resection of the abscess wall;
  Line the abscess cavity with omentum;
  Transfusion of granulocytes.

4.3.3 Pneumonia due to Burkholderia Cepacia

- High doses of Co-trimoxazole: 20-100 (TMP/SMZ) mg/kg/die intravenous infusion in 4 divided doses;
- Transfusion of granulocytes.

4.3.4 Granuloma of the urinary tract

- Prednisone 0.5-1 mg/kg/die for ten days tapering off gradually;
- If treatment fails internal drainage (Pigtail catheter)

4.4 Complementary treatments

4.4.1 Corticosteroids

Corticosteroid treatment should be avoided as it induces secondary immunosuppression. This applies to both topical steroids and inhalants.
The use of prednisone in CGD is justified in some situations as it has proven efficacy in shrinking granulomatous lesions in the urinary tract and attenuating the symptoms of chronic inflammatory bowel disease correlated to immune deficiency.
Low doses of prednisone are sufficient for this purpose: 0.5-1 mg/kg/die per os in two doses for 7-10 days and subsequently withdrawn gradually to avoid relapse.

4.4.2 Transfusion of granulocyte concentrates

Granulocyte transfusions can be given for minor infections which fail to respond to drug management. They can also be administered directly into the abscess cavity after drainage. Granulocyte concentrates are collected from volunteer donors after informed consent and pretreated with subcutaneous G.CSF 5 mcg/kg + Dexamethazone 8 mg per os. 12 hours before leucopheresis to raise the granulocyte count.
Dose : 1 Unit/ Kg.

It has already been mentioned that patients with X-linked CGD must receive transfusions of Kell negative blood products as deletion of the CYBB gene could also affect the Xk locus controlling the expression of kell antigens on the erythrocyte membrane. These patients (with the McLeod phentoype) could therefore deteriorate following repeated transfusions with K+ blood products and risk severe adverse reactions.

4.4.3 G-CSF

Patients with CGDgp 91- presenting residual NADPH oxidase activity can be given the growth factor for granulocytes during acute infection to enhance the respiratory burst of phagocytes.
Dose: 5 mcg/kg/die by subcutaneous injection. Treatment should be suspended in case of neutrophil leucocytosis (G.B.>50 x 10^9/L) and/or thrombocytopenia (PST< 100 x 10^9/L).
Transient abnormalities have been reported including haematuria, proteinuria, raised liver enzymes and anaemia.

4.4.4 Gene therapy

The outcome of a phase I clinical trial on ex vivo gene transfection using retroviral vectors of CD34+ stem cells from patients with CGD gp47phox^0 was recently published. Preliminary findings show that only a small number of positive oxidase neutrophils (1:5000) can be obtained for a short period of time (2-6 months).

This treatment could be used in the future during acute infections in CGD patients in whom even a limited production of genetically correct neutrophils could enhance the immune response.

5. PREVENTION

5.1 How to identify disease carrier status

Functional tests

Carriers of X-linked CGD can be identified by searching for a mosaic pattern of positive and negative oxidase neutrophils using the NBT test, dihydrorodamine cytometric analysis or a search for the gp91 *phox* protein. However, given the random inactivation process of chromosome X, carriers may present an almost normal pattern using these tests.
It is very difficult to identify carriers of autosomal recessive CGD as NADPH oxidase activity and expression of p47, p67 and p22 phox are normal.
Direct mutation analysis is required if p67 and p22 phox expression is normal. When the mutation is known, carrier status can be established by PCR amplification of the DNA genome and subsequent sequence analysis.

5.2 Prenatal diagnosis

Prenatal diagnosis of CGD requires certain diagnosis established in the family as all invasive prenatal diagnostic techniques carry a risk of pregnancy termination. Although this risk is low, it is only justified when there is clear evidence that the family is actually affected by the disease. Before proceeding to prenatal diagnosis, the couple must be offered genetic counselling to give them a detailed picture of disease characteristics and currently available treatments.

In the past prenatal diagnosis was based on the search for CGD biochemical changes in phagocytes obtained from cord blood by funiculocentesis at the 20th week of gestation. However, this procedure has two drawbacks: it yields information late in pregnancy with obvious psychological implications in case of termination, and there is a technical difficulty linked to the low concentration of neutrophil granulocytes in cord blood at that time of gestation.

Nowadays cloning of genes coding for the various subunits of NADPH oxidase will identify the mutation and hence allow prenatal diagnosis by DNA analysis of the chorionic villi at the 15th-16th weeks of gestation. Prenatal diagnosis is possible only when the gene mutation has already been identified in another affected family member. This is one of the reasons gene typing is not recommended for all cases identified. When the mutation is not known, analysis of DNA polymorphisms can be carried out.

6. REFERENCES

Biochemistry and genetics of CGD

1. Landing B.H. et al. A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes. *Pediatrics* 20:431-438, 1957
2. Roos D, Curnutte J.T. Chronic Granulomatous Disease in: Hans D Hochs ed. *Primary Immunodeficiency Diseases*, 353-374, 1999
3. Leusen J.H.W. et al. A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. *J Clin Invest* 93: 2120-2126, 1994
4. Leusen J.H.W. et al. Disturbed interaction of p21-rac with mutated p67-phox causes Chronic Granulomatous Disease. *J Exp Med* 184: 1243-1249, 1996
5. Leusen J.H.W. et al. Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase: consequences for oxidase assembly. *Blood* 95: 666-673, 2000
6. Roos D et al. Mutations in the X-linked and autosomal recessive forms of CGD. *Blood* 87:1663-1681, 1996
7. Patino P.J. et al. Molecular characterization of autosomal recessive Chronic Granulomatous Disease caused by a defect nicotinamide adenine dinucleotide phosphate (reduced form) oxidase component p67-phox. *Blood* 94: 2505-2514, 1999
8. Gorlach A. et al. A p47 phox pseudogene carries the most common mutation causing p47-phox Chronic Granulomatous Disease. *J Clin Invest* 100: 1907, 1997

Clinical aspects

1. Liese J.G. et al.: Chronic Granulomatous Disease in adults. Lancet 347 : 220-223, 1996.
2. Mouy R. et al. Incidence, severity and prevention of infections in Chronic Granulomatous Disease. *J Pediatr* 114: 555-560, 1989
3. Goldblatt D et al. Chorioretinal lesions in patients and carriers of Chronic Granulomatous Disease. *J Pediatr* 134: 780-783, 1999
4. Sponseller P. et al. Skeletal involvement in children with Chronic Granulomatous Disease. *J Bone Joint Surg* 73: 37-51, 1991
5. Barton L. et al. Gastrointestinal complicatons of Chronic Granulomatous Disease. *Clin Pediatr* 37: 231-36, 1998
6. Mc Clellan W et al. The urological manifestations of Chronic Granulomatous Disease. *J Urology* 147: 1314-1318, 1992
7. Payne N. et al. Growth in patients with Chronic Granulomatous Disease. *J Pediatr* 102: 397-399, 1983
8. Brzica S. et al. Chronic Granulomatous Disease and the Mc Leod phenotype. *Mayo Clin Proc* 52: 153, 1977
9. Yeaman G. et al. Discoid lupus erythematosus in an X-linked cytochrome-positive carrier of Chronic Granulomatous Disease. *Br J Dermatol* 126: 60,1992
10. Liese J et al. Long term follow-up and outcome of 39 patients with Chronic Granulomatous Disease. *J Pediatr* 137: 687-693, 2000

Diagnosis

1. Ochs H.D. et al. The NBT slide test : a simple screening method for detecting Chronic Granulomatous Disease and female carriers. *J Pediatr* 83: 77, 1973

2. Porter C.D. et al. Superoxide production by normal and Chronic Granulomatous Disease patient-derived EBV-transformed B cell lines measured by chemiluminescence-based assays. *J Immunol Methods* 155: 151, 1992
3. Mayo L. et al Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol 186: 567, 1990
4. Lutter R. et al. Purification and partial characterization of the b-type cytochrome from human polymorphonuclear leukocytes. *J Biol Chem* 260: 2237, 1985
5. Emmendorfer A et al. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. *J Immunol Methods* 131: 269, 1990
6. Nakamura M. et al. Monoclonal antibody 7D5 raised to cytochrome b558 of human neutrophils: immunocytochemical detection of the antigen in peripheral phagocytes of normal subjects, patients with Chronic Granulomatous Disease, and their carrier mothers. *Blood* 69: 1404, 1987
7. Verhoeven A.J. et al. Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils. *Blood* 73: 1686, 1989

Treatment

1. Fischer A. et al. The management of Chronic Granulomatous Disease. *Eur J Pediatr* 152: 896-899, 1993
2. Seger R. et al. Treatment of Chronic Granulomatous Disease. *Immunodef* 5: 113-130, 1994
3. Margolis D. et al. Trimethoprim-sulfamethoxazole prophylaxis in the management of CGD. *J Infect Dis* 162: 723-726, 1990
4. Mouy R. et al. Long-term itraconazole prophylaxis against Aspergillus infection in 32 patients with CGD. *J Pediatr* 125: 998-1003, 1994
5. Int. Chronic Granulomatous Disease cooperative study group. A controlled trial of interferon gamma to prevent infection in Chronic Granulomatous Disease. *New Engl J Med* 325: 509-516, 1991
6. Weening R.S. et al. Recombinant human interferon-gamma in patients with Chronic Granulomatous Disease- European follow up study. *Eur J Pediatr* 154: 295-298, 1995
7. Condino-Neto A. et al. Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of Chronic Granulomatous Disease due to a splice site consensus region mutation. *Blood* 95: 35-54, 2000
8. Caspar C et al. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocytes colony-stimulating factor (G-CSF). *Blood* 81: 2866-2871, 1993
9. Eckert J et al. The surgical implications of Chronic Granulomatous Disease. *Amer J Surg* 169: 320-323, 1995
10. Danzinger R. et al. Outpatient management with oral corticosteroid therapy for obstructive conditions in CGD. *J Pediatr* 122: 303-305, 1993
11. Schwartz S. et al. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. *Br J Haematol* 97: 663-665, 1997
12. Van't Hek L.G. et al. Successful tratment with voriconazole of invasive aspergillosis in Chronic Granulomatous Disease. *Am J Respir Crit Care Med* 157: 1694-1696, 1998
13. Fukuda T. et al. Treatment with granulocyte colony-stimulating factor for pneumonia in a patient with a variant form of X-linked Chronic Granulomatous Disease. *Eur J Haematol* 55: 63-34, 1995

14. Kamani N. et al. Marrow transplantation in Chronic Granulomatous Disease: an update with six years follow up. *J Pediatr* 113: 696-700, 1988
15. Di Bartolomeo P et al. : Reconstitution of normal neutrophil function in Chronic Granulomatous Disease by bone marrow transplantation. *Bone Marrow Transplant* 4: 695-700, 1989
16. Di Bartolomeo P et al. X-linked cytochrome B positive Chronic Granulomatous Disease treated by bone marrow transplantation. *Hematology* 4: 313-318, 1999
17. Nagler A. et al. Donor lymphocyte infusion post-non-myeoloablative allogeneic peripheral blood stem cell transplantation for Chronic Granulomatous Disease. *Bone Marrow Transplant* 24: 339-342, 1999
18. Malech H. L. et al. Progress in gene therapy for Chronic Granulomatous Disease. *J. Infect Dis.* 179 suppl. 2 : 318-325, 1999

Form A date_______________

Patient's Surname______________________ Name ______________________

Date of birth I_I_I_I_I_I_I
day month year

Referring physician : ……………………………………….………………….
Institution…………………………………...
Address ……………………………………………………………
post code……………. City………………………………….....
Tel…………….… Fax…………………………………..…
e-mail………………………………………………………

Requests quantitative flow cytometric analysis by 123 for:

the patient

the patient's mother: surname_______________________ name ___________________

Send to:

____
____
____
____
____